A Phase 2 interventional study of Oral Vancomycin and Placebo in Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder and IBD, sponsored by University of Milano Bicocca. Recruiting at 1 site in Italy. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-25.
Sponsored by University of Milano Bicocca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing vancomycin in Cholangitis, Sclerosing — 6 open to participants now, 6 under way, none of them phase 3. Vancomycin · Cholangitis, Sclerosing.
Among the 13 studies testing vancomycin in Cholangitis, Sclerosing, this one is the 4th largest by planned enrollment, is the only one that started in 2023, is one of 3 in phase 2, and was the 9th registered.
152 studies on the registry are indexed under Cholangitis, Sclerosing; 42 are open to participants now.
Browse Cholangitis, Sclerosing studies →6 of the 13 studies testing vancomycin in Cholangitis, Sclerosing are open now, in 4 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18+
University of Minnesota · Sites in United States
Ages 18–76
Sacramento Pediatric Gastroenterology · Sites in United States
Ages 2 wk–40 yrs · Healthy volunteers
Yael R. Nobel · Sites in United States
Ages 18+
Tampere University Hospital · Sites in Finland
Ages 6–15
By country, each count listing its studies:
Vancomycin: first FDA approval 1964 (VANCOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 15 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 84 is above the median of 33 across 96 interventional studies indexed under Cholangitis, Sclerosing.
Median enrollment 32 across the 13 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
University of Milano Bicocca is the lead sponsor of 126 studies on the registry; 47 are open to participants now.
University of Milano Bicocca has 2 studies filed under Cholangitis, Sclerosing — fewer than ten, so there is no comparison to draw.
2 of the studies testing vancomycin in Cholangitis, Sclerosing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197308University of MinnesotaEvaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC | 2027-03-31 |
| NCT07945873Yael R. NobelPrimary Sclerosing Cholangitis After Liver Transplant With Oral Vancomycin | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing vancomycin in Cholangitis, Sclerosing, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver. There is still no medical therapy proven to halt the progression of PSC or prevent its serious complications.
This is a Phase 2 randomized, double bind, placebo-controlled, monocentric study evaluating the safety and efficacy of two doses of oral vancomycin (i.e. 750 mg and 1500 mg/day) in subject between 15 - 70 years old with PSC.
Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver characterized by chronic inflammation and sclerosis of the intrahepatic and/or extrahepatic bile ducts, and a risk for progression to liver failure and development of colorectal and hepatobiliary cancer. Both children and adults are affected. Patients with PSC have a diminished life expectancy with a median survival of 17 years after diagnosis. Despite the high mortality associated with PSC and the efforts to optimize its management, there is no medical therapy proven to halt the progression of PSC or prevent its serious complications. There is a strong yet poorly understood relationship between PSC and inflammatory bowel disease (IBD); nearly 70%-80% of PSC patients have IBD, mainly ulcerative colitis (UC). Increasing evidence is pointing out the role of gut microbiota in the pathogenesis of PSC. The 'leaky gut' theory implies that either bacteria or their toxic metabolites translocate from the inflamed intestinal mucosa into the portal circulation and into the liver causing liver and biliary injury. The gut microbiota of PSC patients, compared to IBD patients and healthy controls, showed decreased microbial diversity, and over-represented intestinal pathobionts (i.e., organisms which, under normal circumstances, lives as a non-harming symbiont). Several antibiotics, including vancomycin and metronidazole, have been investigated in PSC. The use of oral vancomycin (OV), a glycopeptide antibiotic has been reported to be associated with improvement in clinical symptoms and laboratory abnormalities in patients with PSC; however, prospective studies in adult and young adult patients in Europe are lacking.
Our scientific community therefore seeks to examine the safety and efficacy of OV in patients with PSC in a randomized placebo-controlled clinical trial.
This is a Phase 2 randomized, double bind, placebo-controlled, monocentric study evaluating the safety and efficacy of two doses of oral vancomycin (i.e. 750 mg and 1500 mg/day) in subject between 15 - 70 years old with PSC with or without IBD. The study will consist of 10-week screening period (including a run-in phase), 24 weeks of treatment, and follow-up visits at 4 and 12 weeks after completion of treatment to evaluate what happens after treatment stop. Subjects will be randomized to placebo or treatment and stratifying by baseline presence of fibrosis by fibroscan value at baseline (\< or ≥14.4 kPa corresponding to F4 fibrosis), as this parameter could affect the likelihood of reaching the primary composite outcome measure.
The knowledge gained from our proposed clinical trial will help us determine if OV should be considered as a treatment option in patients with PSC. Furthermore, the use of state-of-the art technology applied in this study will shed light on the relationship between the gut microbiome, bile acids, immune-mediators, including cytokines, and PSC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
28 subjects with PSC will be randomized to this arm. They will take 2 tablet (1 of vancomycin 250 mg and 1 of placebo), three times a day administered orally (total dose 750 mg/daily).
Drug: Oral Vancomycin
28 subjects with PSC will be randomized to this arm.They will take 2 tablet of 250 mg of vancomycin three times a day administered orally (total dose 1500mg/daily)
Drug: Oral Vancomycin
28 subjects with PSC will be randomized to this arm. They will take 2 tablet (placebo-to-match oral vancomycin) administered orally three times a day.
Other: Placebo
The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
Also known as: OV
The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
Change from baseline in alkaline phosphatase (ALP) levels
ALP levels at 6 months
Time frame: From baseline to 6 months
Safety and tolerability of OV in each treatment arm
Adverse events
Time frame: From baseline to 6 months
Clinical hematology
White blood cells (10\^3/uL)
Time frame: From baseline to 6 months
Clinical hematology
Hemoglobin (g/dl)
Time frame: From baseline to 6 months
Clinical hematology
Hematocrit (%)
Time frame: From baseline to 6 months
Clinical hematology
MCV (Mean Corpuscular Volume) (fL)
Time frame: From baseline to 6 months
Clinical hematology
Platelets (10\^3/uL)
Time frame: From baseline to 6 months
Clinical hematology
Absolute neutrophils (10\^3/uL)
Time frame: From baseline to 6 months
Clinical hematology
Absolute lymphocytes (10\^3/uL)
Time frame: From baseline to 6 months
Clinical hematology
PT (Prothrombin Time, Ratio)
Time frame: From baseline to 6 months
Clinical hematology
INR
Time frame: From baseline to 6 months
Clinical chemistry
Total proteins (g/dl)
Time frame: From baseline to 6 months
Clinical chemistry
Albumin (g/dl)
Time frame: From baseline to 6 months
Clinical chemistry
Gamma (g/dl)
Time frame: From baseline to 6 months
Clinical chemistry
Sodium (mmol/l)
Time frame: From baseline to 6 months
Clinical chemistry
Creatinine (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
Potassium (mmol/l)
Time frame: From baseline to 6 months
Clinical chemistry
Urea (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
Glucose (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
Total bilirubin (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
Direct bilirubin (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
GGT (U/l)
Time frame: From baseline to 6 months
Clinical chemistry
AST (U/l)
Time frame: From baseline to 6 months
Clinical chemistry
ALT (U/l)
Time frame: From baseline to 6 months
Clinical chemistry
Triglycerides (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
Cholesterol (Total) (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
High Density Lipoprotein (HDL Cholesterol) (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
PCR (C Reactive Protein) (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
IgG (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
IgA (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
IgM (mg/dl)
Time frame: From baseline to 6 months
Clinical chemistry
Ferritin (ng/ml)
Time frame: From baseline to 6 months
Single 12-lead electrocardiograms
Sinus rhythm
Time frame: From baseline to 6 months
Single 12-lead electrocardiograms
QTc (msec)
Time frame: From baseline to 6 months
Urine analysis
pH
Time frame: From baseline to 6 months
Urine analysis
Specific gravity
Time frame: From baseline to 6 months
Urine analysis
Hemoglobin
Time frame: From baseline to 6 months
Urine analysis
ACR (mg/g)
Time frame: From baseline to 6 months
Urine analysis
PCR (mg/g)
Time frame: From baseline to 6 months
Vital sign measurements
Body weight (kg)
Time frame: From baseline to 6 months
Vital sign measurements
Systolic blood pressure (mmHg)
Time frame: From baseline to 6 months
Vital sign measurements
Diastolic blood pressure (mmHg)
Time frame: From baseline to 6 months
Vital sign measurements
Heart Rate (bpm)
Time frame: From baseline to 6 months
Vital sign measurements
Temperature (°C)
Time frame: From baseline to 6 months
Changes in the PSC score
Revised Mayo Risk Score (Calculation formula = 0.03 (age \[y\]) + 0.54 loge (bilirubin \[mg/dL\]) + 0.54 loge (aspartate aminotransferase \[U/L\]) + 1.24 (variceal bleeding \[0/1\]) - 0.84 (albumin \[g/dL\]) (Higher scores indicate greater disease severity)
Time frame: From baseline to 6 months
Changes in the IBD score
Clinical Mayo Score (Partial Mayo Score) -(0-1=Remission; 2-4 = Mild activity; 5-7 = Moderate activity; 7-9 = Severe activity)
Time frame: From baseline to 6 months
Liver stiffness measurements
Stiffness (kPa/s)
Time frame: From baseline to 6 months
Liver stiffness measurements
Stiffness IQR/median (%)
Time frame: From baseline to 6 months
Liver stiffness measurements
CAP (dB/m)
Time frame: From baseline to 6 months
Liver stiffness measurements
CAP IQR/median (%)
Time frame: From baseline to 6 months
MRCP (Magnetic Resonance Cholangiopancreatography)
Disease localisation
Time frame: From baseline to 6 months
MRCP (Magnetic Resonance Cholangiopancreatography)
Presence of dominant stenosis
Time frame: From baseline to 6 months
MRCP (Magnetic Resonance Cholangiopancreatography)
Radiological signs of cirrhosis
Time frame: From baseline to 6 months
Cytokines changes
TGF-β levels
Time frame: From baseline to 6 months
Cytokines changes
IL-4 levels
Time frame: From baseline to 6 months
Cytokines changes
IL-13 levels
Time frame: From baseline to 6 months
Cytokines changes
IL-10 levels
Time frame: From baseline to 6 months
Changes in the peripheral blood mononuclear cells
Th1 and Th17 subsets isolation and analyses
Time frame: From baseline to 6 months
Patients quality of life
Visual analogue scale (VAS) score for itch
Time frame: From baseline to 6 months
Patients quality of life
Chronic Liver Disease Questionnaire (CLDQ)
Time frame: From baseline to 6 months
Patients quality of life
EQ-5D-5L questionnaire
Time frame: From baseline to 6 months
Patients quality of life
PSC patient reported outcome (PSC-PRO) questionnaire
Time frame: From baseline to 6 months
Patients quality of life
Inflammatory Bowel Disease Questionnaire (IBDQ)
Time frame: From baseline to 6 months
Plan to share: No
Started Jun 2023 (actual). Primary completion is estimated for Jun 2026, 36 months after the start.
Of 23 phase 2 interventional studies under Cholangitis, Sclerosing, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's planned 36 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vancomycin
University of Milano Bicocca →